Copied
 
 
Formål
HistorikStartStop
Selskabets formål er at opsamle, eje og udvikle know how og patentrettigheder til at måle blodkoncentrationer af små-molekyle medikamenter og at kommercialisere disse rettigheder ved egne aktiviteter eller ved at lave licensaftaler med samarbejdspartnere, samt enhver aktivitet der efter bestyrelsens skøn står i forbindelse hermed20.02.201521.01.2021
Virksomheden har ikke ændret Formål i sin levetid.
Ingen nuværende registrering.
Status
HistorikStartStop
OPLØST EFTER FUSION21.01.202121.01.2021
NORMAL20.02.201520.01.2021
Ingen nuværende registrering.
Branche
HistorikStartStop
Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)01.04.201521.01.2021
Uoplyst (999999)20.02.201531.03.2015
Ingen nuværende registrering.
Revision
HistorikStartStop
false20.02.201521.01.2021
Virksomheden har ikke ændret Revision i sin levetid.
Ingen nuværende registrering.
Revisor
HistorikStartStop
DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB20.02.201521.01.2021
Virksomheden har ikke ændret Revisor i sin levetid.
Ingen nuværende registrering.
Form
HistorikStartStop
8020.02.201521.01.2021
Virksomheden har ikke ændret Form i sin levetid.
Ingen nuværende registrering.
Kontakt
Ingen nuværende registrering.
Ingen historik.
Telefon
Ingen nuværende registrering.
Ingen historik.
Navne
Ingen nuværende registrering.
Binavne
HistorikStartStop
UNISENSE DETECT ApS20.02.201521.01.2021
UNISENSE HEALTH ApS20.02.201521.01.2021
Ingen nuværende registrering.
Tegningsregel
HistorikStartStop
Selskabet tegnes af én direktør eller af den samlede direktion22.08.201921.01.2021
Selskabet tegnes af direktøren i forening med et bestyrelsesmedlem, eller af den samlede bestyrelse20.02.201521.08.2019
Ingen nuværende registrering.
Ansatte
03.11.2024
Ingen historik.
Kapital
03.11.2024
Fra årsrapport
Type af revisorbistand:Revisionspåtegning
Virksomhedens regnskabsklasse:Regnskabsklasse B
Grundlag for konklusion (revision):We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor’s responsibilities for the audit of the financial statements" section of this auditor’s report. We are independent of the Entity in accordance with the International Ethics Standards Board of Accountants' Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Konklusion (revision):We have audited the financial statements of Unisense Diagnostics ApS for the financial year 01. 01. 2019 - 31. 12. 2019, which comprise the income statement, balance sheet, statement of changes in equity and ​notes, including a summary of significant accounting policies. The financial statements are prepared in accordance with the Danish Financial Statements Act. ​ ​In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31. 12. 2019 and of the results of its operations for the financial year 01. 01. 2019 - 31. 12. 2019 in accordance with the Danish Financial Statements Act.
Udtalelse om ledelsesberetningen (revision):Management is responsible for the management commentary. Our opinion on the financial statements døs not cover the management commentary, and we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the management commentary and, in doing so, consider whether the management commentary is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. Moreover, it is our responsibility to consider whether the management commentary provides the information required under the Danish Financial Statements Act. Based on the work we have performed, we conclude that the management commentary is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statements Act. We did not identify any material misstatement of the management commentary.
Bibranche
Ingen nuværende registrering.
Ingen historik.
Børsnoteret
03.11.2024
Ingen nuværende registrering.
Ingen historik.
Hjemmeside
03.11.2024
Ingen nuværende registrering.
Ingen historik.